The preclinical pharmacology of roflumilast–a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease
A Hatzelmann, EJ Morcillo, G Lungarella… - Pulmonary …, 2010 - Elsevier
After more than two decades of research into phosphodiesterase 4 (PDE4) inhibitors, roflumilast
(3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may …
(3-cyclopropylmethoxy-4-difluoromethoxy-N-[3,5-di-chloropyrid-4-yl]-benzamide) may …
Mucus and MUC in asthma
EJ Morcillo, J Cortijo - Current opinion in pulmonary medicine, 2006 - journals.lww.com
Airway mucus hypersecretion as a part of airway remodelling represents a problem in
asthma, and studies of pathophysiology and therapeutic approaches are therefore warranted. …
asthma, and studies of pathophysiology and therapeutic approaches are therefore warranted. …
PDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expression
MJ Sanz, J Cortijo, EJ Morcillo - Pharmacology & therapeutics, 2005 - Elsevier
Phosphodiesterase 4 (PDE4) is a major cyclic AMP-hydrolyzing enzyme in inflammatory
and immunomodulatory cells. The wide range of inflammatory mechanisms under control by …
and immunomodulatory cells. The wide range of inflammatory mechanisms under control by …
Menopause and ovariectomy cause a low grade of systemic inflammation that may be prevented by chronic treatment with low doses of estrogen or losartan
…, AC Issekutz, PJ Jose, J Cortijo, EJ Morcillo… - The Journal of …, 2009 - journals.aai.org
The incidence of cardiovascular diseases in premenopausal women is lower than in men or
postmenopausal women. This study reports the discovery of a low grade of systemic …
postmenopausal women. This study reports the discovery of a low grade of systemic …
[HTML][HTML] In vivo antioxidant treatment protects against bleomycin-induced lung damage in rats
…, J Cortijo, JM Estrela, EJ Morcillo… - British journal of …, 2003 - ncbi.nlm.nih.gov
… A Serrano-Mollar, 1 D Closa, 1 N Prats, 2 S Blesa, 3 M Martinez-Losa, 3 J Cortijo, 3 JM
Estrela, 4 EJ Morcillo, 3, * and O Bulbena 1 … CORTIJO J., CERDA-NICOLAS M …
Estrela, 4 EJ Morcillo, 3, * and O Bulbena 1 … CORTIJO J., CERDA-NICOLAS M …
Attenuation by oral N-acetylcysteine of bleomycin-induced lung injury in rats
…, A Llombart-Bosch, EJ Morcillo - European …, 2001 - Eur Respiratory Soc
Antioxidant therapy may be useful in diseases with impaired oxidant-antioxidant balance
such as pulmonary fibrosis. This study examines the effect of N-acetylcysteine (NAC) on …
such as pulmonary fibrosis. This study examines the effect of N-acetylcysteine (NAC) on …
Roflumilast, a phosphodiesterase 4 inhibitor, alleviates bleomycin‐induced lung injury
…, H Tenor, A Hatzelmann, EJ Morcillo - British journal of …, 2009 - Wiley Online Library
Mandarin translation of abstract Background and purpose: The effects of a phosphodiesterase
4 (PDE4) inhibitor, roflumilast, on bleomycin‐induced lung injury were explored in ‘…
4 (PDE4) inhibitor, roflumilast, on bleomycin‐induced lung injury were explored in ‘…
Phosphodiesterase 4 inhibition decreases MUC5AC expression induced by epidermal growth factor in human airway epithelial cells
…, A Buenestado, J Cortijo, M Cerda, EJ Morcillo - Thorax, 2005 - thorax.bmj.com
Background: A common pathological feature of chronic inflammatory airway diseases such
as asthma and chronic obstructive pulmonary disease (COPD) is mucus hypersecretion. …
as asthma and chronic obstructive pulmonary disease (COPD) is mucus hypersecretion. …
Trans-but not Cis-resveratrol impairs angiotensin-II–mediated vascular inflammation through inhibition of NF-κB activation and peroxisome proliferator-activated …
…, AC Issekutz, L Estan, J Cortijo, EJ Morcillo… - The Journal of …, 2010 - journals.aai.org
Angiotensin II (Ang-II) displays inflammatory activity and is implicated in several cardiovascular
disorders. This study evaluates the effect of cis-and trans (t)-resveratrol (RESV) in two in …
disorders. This study evaluates the effect of cis-and trans (t)-resveratrol (RESV) in two in …
Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines
…, M Mata, J Zagorski, H Sarau, J Cortijo, EJ Morcillo… - Circulation, 2004 - Am Heart Assoc
Background— Angiotensin II (Ang II) is implicated in the development of cardiac ischemic
disorders in which prominent neutrophil accumulation occurs. Ang II can be generated …
disorders in which prominent neutrophil accumulation occurs. Ang II can be generated …